Affimed GmbH

Technologiepark
Im Neuenheimer Feld 582
69120 Heidelberg
GErmany

Website: www.affimed.com

Industry sector: Biotechnology
Products/services: Bispecific antibodies to activate the innate immune system of patients with cancer (currently in pre-clinical and clinical development)
Location(s): Heidelberg, Germany
New York City, USA
Date of foundation: 2000
Number of employees: 169
About the company/organisation: Affimed (Nasdaq: AFMD) is a clinical-stage immuno-oncology company committed to give patients back their innate ability to fight cancer by actualizing the untapped potential of the innate immune system. The company’s proprietary ROCK® platform enables a tumor-targeted approach to recognize and kill a range of hematologic and solid tumors, enabling a broad pipeline of wholly owned and partnered single agent and combination therapy programs. The ROCK® platform predictably generates customized innate cell engager (ICE®) molecules, which use patients’ immune cells to destroy tumor cells. This innovative approach enabled Affimed to become the first company with a clinical-stage ICE®. Headquartered in Heidelberg, Germany, with offices in New York, NY, Affimed is led by an experienced team of biotechnology and pharmaceutical leaders united by a bold vision to stop cancer from ever derailing patients’ lives.
 
Recruitments per year: 40
Area of expertise:

Biowissenschaften

Biochemie

Biotechnologie

Chemie

Program Management

Quality Assurance

Regulatory Affairs

Clinical Operations

Statistics

Last degree:

PostDoc

PhD

Master

Bachelor

Technische Assistenten

Desired additional skills (soft skills): Good English language skills are favorable
Career opportunities: Direct entry
Trainee program: No
Contact: Affimed GmbH
Susanne Hering
Im Neuenheimer Feld 582
69120 Heidelberg
s.hering [at] affimed.com